Hyoscine butylbromide (Juposci)
Hyoscine butylbromide
Adcock Ingram Healthcare (Pty) Ltd - Clayville
Registration
- Applicant
- Adcock Ingram Healthcare (Pty) Ltd - Clayville
- Certificate holder
- Adcock ingram limited
- Registrations
- 1
- Schedule source
- SAHPRA documentation
Variants
Regulatory status
Where S1 sits on the scale
Sold by a pharmacist, no doctor's prescription needed.
Schedule 1 medicines are normally sold by a pharmacist, or by a supervised pharmacist intern or assistant, without a doctor's visit; a veterinarian, or a licensed dispensing doctor, dentist or nurse prescriber, may also supply them. A nurse or other non-doctor prescriber may only prescribe the specific substances the Schedule names for that purpose, and may only dispense them if licensed to do so. A child under 12 may only be sold one of these medicines on a prescription, or on a written order that names the purpose and carries a signature the seller recognises.
Schedule S1, read from the product's PI-PIL leaflet.
The Consolidated Schedules list this ingredient up to S3; the leaflet's S1 applies to this product.
Who may supply: A pharmacist, or a supervised pharmacist intern or assistant; manufacturers and wholesalers supplying people who may lawfully possess it; a veterinarian, who may prescribe, compound or dispense it; a medical practitioner or dentist, who may prescribe it, and may compound or dispense it only if licensed under section 22C(1)(a); a nurse or other registered non-doctor prescriber, who may prescribe only the Scheduled substances the Schedule identifies for that purpose, and dispense them if licensed to do so; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Hyoscine butylbromide
S3: Hyoscine butylbromide
- substances, preparations and mixtures thereof-
- except when intended for oral administration; (S1, S2) and
- except transdermal preparations when intended for the prevention of the symptoms of motion sickness. (S2)
Consolidated Schedules 06 July 2026, lines 3727 to 3732
S2: Hyoscine butylbromide
- substances, preparations and mixtures thereof-
- when intended for oral administration in pack sizes exceeding 20 tablets or 100 ml, or strengths exceeding 10 mg per oral solid dosage form or 0.1% mass/ volume; (S1)
- transdermal preparations when intended for the prevention of the symptoms of motion sickness; (S3)
- except when intended for parenteral administration. (S3)
Consolidated Schedules 06 July 2026, lines 2119 to 2124
S1: Hyoscine butylbromide
- substances, preparations and mixtures thereof-
- when intended for oral administration in pack sizes not exceeding 20 tablets of 10 mg strength or less, or 100 ml of oral liquid dosage of 0.1% mass/ volume or less; (S2)
- except transdermal preparations when intended for the prevention of the symptoms of motion sickness; (S2)
- except when intended for parenteral administration. (S3)
Consolidated Schedules 06 July 2026, lines 523 to 529
Pharmacological class: Gastro-intestinal antispasmodics and cholinolytics (anticholinergics). (class 11.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
Schedule Verification
This medication's schedule (S1) has been verified from official SAHPRA documents with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.